Venue
Charles K. Kao Auditorium, Hong Kong Science Park, Hong Kong
Upcoming Events
Upcoming Events
https://www.med.cuhk.edu.hk/upcoming-events/HITS2022https://www.med.cuhk.edu.hk/upcoming-events/HITS2022
Healthcare Innovation and Technology Summit 2022
Overview
| Healthcare Innovation and Technology Summit 2022 (HITS 2022) | |||
|---|---|---|---|
Date: | 14 October 2022 (Friday) | ||
Time: | 9AM - 5PM (HKT) | ||
Venue: | Charles K. Kao Auditorium, Hong Kong Science Park, Hong Kong | ||
| Format: | Hybrid (Physical & Online Streaming) | ||
| Language: | English | ||
Healthcare Innovation and Technology Summit 2022(HITS 2022) brings together global innovation and healthcare leaders, and young talents for knowledge transfer and exchange amongst the BIG QUESTIONS and BIG PERSPECTIVES that hit you.
- Co-organised by the Faculty of Medicine of The Chinese University of Hong Kong (CU Medicine) and Hong Kong Science and Technology Parks Corporation (HKSTP), and in celebration of CU Medicine’s 40th Anniversary and HKSTP’s 20th Anniversary
- Stage some of the most influential speakers in healthcare and innovation
- Showcase R&D success stories and remarkable outcomes in Hong Kong
- Provide opportunities for talents and investment on both start-up businesses and established projects
Who Should Attend?
- Government officials and regulators
- Medical academic and healthcare professionals
- Business leaders and industry players from medical, healthcare, innovation, science and technology sectors
- Investors and venture capitalists
- Healthcare, innovation and technology start-ups and entrepreneurs
- Media focus on medical and technology
Why Should You Attend?
- A comprehensive and innovative programme: Panel discussions covering Successful Translational Research Projects, Intellectual Property & Patent Protection for InnoHealth, Opportunities & Challenges in Cancer Management, Healthcare Innovation & Investment Opportunities, CU Medicine & HKSTP’s Strategies and Resources in Nurturing Young Talents
- Heavyweight moderators and speakers: Meet and connect with the thought-provoking leaders in healthcare and innovation
- Guided tours to CUHK’s InnoHK Centres and HKSTP's Experience Centre
- Exhibition of CUHK InnoHealth Start-ups and R&D stories: Chat with the aspiring entrepreneurs and explore collaboration
Co-organisers
.png) | .png) |
|---|
Supporting Organisations
.png) | .png) |  | .png) |
|---|
Transportation
GET TO SCIENCE PARK BY CAR
Drive to Science Park via the Tolo Highway. Your trip should take 30 minutes from Tsim Sha Tsui, and 30 minutes from Shenzhen.
Find out the parking rates and car park rules and regulations here.
BY TRAIN
Science Park is minutes away from the University and Shatin MTR stations, which you can get to via the East Rail Line. From University station, take the 272K bus to get to the Science Park. From Shatin station, take the 27 minibus.
BY BUS
Get to Science Park via a wide range of Kowloon Motor Bus (KMB) and green minibus routes and from transport hubs all around Hong Kong.
| 272K | Between Mass Transit Railway (MTR) University Station Bus Terminus and Science Park |
| 272S | Between MTR Diamond Hill Station Bus Terminus and Science Park |
| 43P | Between MTR Tsuen Wan West Station Bus Terminus and Science Park |
| 74D | Between Kwun Tong Ferry Bus Terminus and Tai Po Kau Lung Hang (via Science Park) |
| 74P | Between Kwun Tong Ferry Bus Terminus and Tai Po Central (via Science Park) |
| 82C | Between Shatin Kwong Yuen Bus Terminus and Science Park (Phase 3) |
| 263A | Between Tuen Mun Station and Science Park (Phase 3) |
| 272A | Between University Station and Pak Shek Kok (Circular - via Science Park) |
| 272P | Between Tai Po Fu Heng Bus Terminus and Kwai Hing Station (via Science Park) |
| Between Tai Po Fu Heng Bus Terminus and Kwai Hing Station (via Science Park) | |
| Between Tsim Sha Tsui Middle Road and Tai Po Fu Heng Bus Terminus (via Science Park) | |
GREEN MINIBUS NO. 27 | Between Sha Tin MTR Station (Pai Tau Street) and Science Park |
| Between Ma Liu Shui Ferry Pier and Wan Tau Tong (via Pak Shek Kok) | |
| Between Wong Nai Tau and Wan Tau Tong (via Pak Shek Kok) | |
| Between Shek Mun and Wan Tau Tong (via Pak Shek Kok) |
Contact Us
9:00 – 9:25 Opening Session
Welcome Remarks
Professor Francis CHAN, SBS, JP, a world-renowned clinician-scientist in gastrointestinal diseases, is Choh-Ming Li Professor of Medicine and Therapeutics and Dean of Medicine of The Chinese University of Hong Kong (CUHK). He serves as a senior associate editor of a leading international journal, Board Member of the Hospital Authority, and co-director of the Microbiota I-Center (MagIC) established under the Innovation and Technology Commission. Professor CHAN has led large-scale, multi-centered drug trials of international pharmaceutical companies. In 2019, Professor CHAN co-founded a microbiota start-up company, GenieBiome Company Limited, to transform scientific innovations into clinical applications. Currently, he is the non-executive Chairman of Board of Directors and Scientific Advisor of the Company.
Welcome Remarks
As HKSTP’s CEO since 2016, Albert leads the team on a mission to support and grow tech ventures in the city’s largest R&D hub of 11,000+ professionals and 1,100 companies, with a focus on commercialising R&D into successful innovation with impact. Through 30+ years of commercial, industrial and leadership roles with various multinationals including GE Oil & Gas China and GE Industrial Solutions Asia Pacific, he has accumulated insight and critical understanding of building companies, investment networks and solving market needs. Albert holds an Engineering Degree from HKU and an MBA from CUHK.
9:25 – 10:25 Translational Research: From Concepts into Healthcare Innovation (Session I) 
Moderators:
Professor Francis CHAN, SBS, JP, a world-renowned clinician-scientist in gastrointestinal diseases, is Choh-Ming Li Professor of Medicine and Therapeutics and Dean of Medicine of The Chinese University of Hong Kong (CUHK). He serves as a senior associate editor of a leading international journal, Board Member of the Hospital Authority, and co-director of the Microbiota I-Center (MagIC) established under the Innovation and Technology Commission. Professor CHAN has led large-scale, multi-centered drug trials of international pharmaceutical companies. In 2019, Professor CHAN co-founded a microbiota start-up company, GenieBiome Company Limited, to transform scientific innovations into clinical applications. Currently, he is the non-executive Chairman of Board of Directors and Scientific Advisor of the Company.
Professor YUNG Shu-Hang Patrick, Chairman of the Department of Orthopaedics and Traumatology, and Assistant Dean (Alumni Affairs), Faculty of Medicine, The Chinese University of Hong Kong, focuses on Orthopaedics sport medicine and arthroscopy surgery.
He serves as the leader for international & local sports medicine centres, e.g. President of the Asian Federation of Sports Medicine (AFSM) and President of the Hong Kong Association of Sports Medicine & Sports Science (HKASMSS). He is also the Director of Hong Kong Centre of Sports Medicine and Sports Science, Hong Kong Jockey Club Sports Medicine and Health Sciences Centre, and Centre of Neuromusculoskeletal Restorative Medicine (CNRM) of InnoHK.
Panelists:
Professor Dennis LO is the Associate Dean (Research) of the Faculty of Medicine of The Chinese University of Hong Kong, and the Founding Scientific Director of the Centre for Novostics under the InnoHK scheme. Professor LO discovered the presence of cell-free fetal DNA in maternal blood in 1997. He has spearheaded the development of non-invasive prenatal testing (NIPT) which is now used worldwide. He has also pioneered technologies for the detection of cancer using peripheral blood. His technologies have underpinned recently launched tests for multi-cancer early detection (MCED). He has won numerous awards, including the Breakthrough Prize (2021).
Professor Siew NG is Director of the Microbiota I-Center (MagIC), Assistant Dean (Development) and Professor at the Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong. She is also Scientific co-founder of GenieBiome Limited. She is a world-leading pioneer in research in inflammatory bowel disease, human gut microbiota and fecal microbiota transplantation. As an entrepreneur-scientist, her work aims to translate microbiome knowledge to novel diagnostic and therapeutic innovations to improve human health. She has published over 310 papers and was awarded Women of Power by Prestige in 2021 and Highly-cited researchers by Clarivate in 2020 and 2021.
10:25 – 10:40 Networking Break
10:40 – 11:00 Intellectual Property and Patent Protection for InnoHealth 
Moderators:
Professor Dennis LO is the Associate Dean (Research) of the Faculty of Medicine of The Chinese University of Hong Kong, and the Founding Scientific Director of the Centre for Novostics under the InnoHK scheme. Professor LO discovered the presence of cell-free fetal DNA in maternal blood in 1997. He has spearheaded the development of non-invasive prenatal testing (NIPT) which is now used worldwide. He has also pioneered technologies for the detection of cancer using peripheral blood. His technologies have underpinned recently launched tests for multi-cancer early detection (MCED). He has won numerous awards, including the Breakthrough Prize (2021).
Professor WU is the Associate Dean (Health Systems) of Faculty of Medicine of The Chinese University of Hong Kong (CUHK), the Chairman of CUHK Medical Services, and the President of Asian Pacific Association of Gastroenterology. He is the former Chief Operating Officer of CUHK Medical Centre, the private teaching hospital of CUHK. In medical education, Professor WU is the founding director of Asia’s first “Global Physician-Leadership Stream” (GPS), which has been the top undergraduate programme in Hong Kong since its inception in 2013. In the field of medical innovation, he is serving as director and advisor of biomedical technology companies and investment funds in Hong Kong.
Panelists: 
Professor AU Kwok Wai Samuel received the Ph.D. degree in mechanical engineering from MIT in 2007. He is currently a Professor with the Department of Mechanical and Automation Engineering, The Chinese University of Hong Kong and the Founding Director of Multi-Scale Medical Robotics Center, InnoHK. Dr. AU is also the president of Cornerstone Robotics that he found in September 2019. Before joining CUHK, he was a manager of Systems Analysis at Intuitive Surgical. He co-invented the FDA approved da Vinci Single-Site platform and was also a founding team member for the da Vinci ION system. Dr. AU co-authored over 17 granted US patents/EP.
Jennifer CHE is Vice President and Principal at Eagle IP and a US Patent Attorney. She has a deep understanding of the biopharmaceutical industry, having worked as a chemist, executive, and patent attorney over her 20+ year career. Jennifer spent over 10 years at Vertex Pharmaceuticals (USD70 billion S&P500 company) in Boston before joining the start-up world, most notably as head of IP at Axcella Therapeutics (a Flagship company). Jennifer moved to Hong Kong in 2017 and has been at Eagle IP for over four years. Jennifer holds a chemistry degree from MIT and a Juris Doctor (JD) from Suffolk Law in Boston.
Prof. Benny ZEE is the Director of the Office of Research and Knowledge Transfer Services (ORKTS), Professor/Director of the Centre for Clinical Research and Biostatistics, JC School of Public Health and Primary Care, The Chinese University of Hong Kong. Professor Zee obtained his PhD in Biostatistics from the University of Pittsburgh, USA in 1987. He then joined the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), currently known as Senior Biostatistician. He has a strong interest in various aspects of multi-centre clinical trials, biostatistics and bioinformatics methods, drugs and medical device development, and extensive experience in knowledge transfer activities.
11:40 – 12:40 Opportunities and Challenges in Cancer Management: From Research to Clinical Application
(Pre-recorded video)
Moderators: 
Professor Anthony CHAN is currently Pro-Vice-Chancellor/Vice-President of The Chinese University of Hong Kong, Li Shu Fan Medical Foundation Professor of Clinical Oncology, Director of the Sir YK Pao Centre for Cancer, Director of Hong Kong Cancer Institute, Chief Director of Phase 1 Clinical Trial Centre, Associate Director of State Key Laboratory for Translational Oncology (CUHK), and Master of Wu Yee Sun College.
Professor CHAN conducted pivotal studies defining new treatment standards for multimodality approaches to nasopharynx cancer, developed the clinical applications of the biomarker EBV DNA and pioneered the development of immunotherapeutic and targeted therapeutics for this disease. He has published extensively in international journals and delivered hundreds of international lectures. He has served on the Editorial Board of Journal of Clinical Oncology and has been Associate Editor of Annals of Oncology since 2014.
Professor Philip CHIU is Director of Multi-Scale Medical Robotics Center, Professor and Chief of Upper GI and Metabolic Surgery, Department of Surgery, The Chinese University of Hong Kong.
Working at the forefront of endoscopic, minimally invasive and robotic surgery, Prof CHIU has pioneered and fostered clinical translation of many endoscopic and robotic innovations. He was the first in Hong Kong to perform ESD for treatment of early GI cancers in 2004, POEM in 2010, followed by the world’s first robotic gastric ESD and colorectal ESD in 2011 and 2020 respectively. He has published over 370 peer reviewed manuscripts and earned numerous accolades including the State Scientific Technology and Progress Award from People’s Republic of China.
Panelists:
(Pre-recorded video)Professor DARZI is Co-Director of the Institute of Global Health Innovation and Paul Hamlyn Chair of Surgery at Imperial College London. He is Consultant Surgeon at Imperial College NHS Trust and the Royal Marsden NHS Foundation Trust and Chair of the Pre-emptive Medicine and Health Security Initiative at Flagship Pioneering.
In 2002, he was knighted for his services in medicine and surgery, and introduced to the United Kingdom’s House of Lords as Professor the Lord DARZI of Denham in 2007. He has been a member of the Privy Council since 2009 and was awarded the Order of Merit in 2016.
Professor Tony MOK is Chairman of ACT Genomics, Li Shu Fan Medical Foundation Professor of Clinical Oncology and Chairman of Department of Clinical Oncology at The Chinese University of Hong Kong. He is leading Investigator of multiple randomized studies including IPASS, AURA3, IMPRESS, KEYNOTE 042, FASTACT 2, ARCHER 1050, ALEX and PROFILE 1014.
His work was recognised by numerous awards including Bonnie Addario Award in 2015, Fellowship of the American Society of Clinical Oncology (FASCO) in 2017, Paul Bunn Jr Scientific Award in 2017, National Science and Technology Progress Award in 2017, CSCO Annual Achievement Award in 2017, ESMO Lifetime Achievement Award in 2018, The 6th Kobayashi Foundation Award, Giant of Cancer Care 2020 and SingTao Hong Kong Leader of the Year 2020 Award. His is one of the “Highly Cited Researchers” by Clarivate Analytics for four consecutive years from 2018 to 2021.
Professor YU Jun is Choh-Ming Li Professor of Medicine and Therapeutics, Assistant Dean of Faculty of Medicine, Director of Institute of Digestive Disease, Director of State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong. She served as Council Member of American Gastrointestinal Association (AGA) Microbiome & Microbial Therapy (MMT) (2018-2022) and Council Member of AGA Oncology (2017-2018); Vice-Chairman of Cancer and Gut Microbiome of Anti-Cancer Association China; her research interests being molecular pathogenesis, microbiome, diagnostic biomarkers and therapeutic targets of gastrointestinal cancers and fatty liver disease. She has over 520 peer-reviewed publications (184 papers IF>10; 90 papers with IF>30; ISI citation>26,000, ISI h-index=86).
14:00 – 15:00 A Pioneering Role of HKSTP in Nurturing Young Talents
Moderator: 
As HKSTP’s CEO since 2016, Albert leads the team on a mission to support and grow tech ventures in the city’s largest R&D hub of 11,000+ professionals and 1,100 companies, with a focus on commercialising R&D into successful innovation with impact. Through 30+ years of commercial, industrial and leadership roles with various multinationals including GE Oil & Gas China and GE Industrial Solutions Asia Pacific, he has accumulated insight and critical understanding of building companies, investment networks and solving market needs. Albert holds an Engineering Degree from HKU and an MBA from CUHK.
Panelists:
Dr. LEUNG is the Founder, Chairman and Chief Executive Officer of SinoMab BioScience Limited. Currently, he is also a Member of the Biotech Advisory Panel of The Stock Exchange of Hong Kong Limited and a Non-official Director of the Hong Kong Genome Institute.
Dr. LEUNG has over 30 years of experience in the field of molecular immunology and therapeutic monoclonal antibodies. He was the first scientist who successfully developed humanised anti-CD22 antibody and introduced the concept of “Functional Humanisation”. Dr. LEUNG currently also serves as an Adjunct Professor at The Hong Kong University of Science and Technology, The Army Medical University (formerly known as the Third Military Medical University) and The Air Force Medical University (formerly known as the Fourth Military Medical University) in Mainland China. He also held positions as the Executive Director of a leading US antibody-drug conjugate company, the Managing Director of The Hong Kong Institute of Biotechnology Limited, as well as the Adjunct Professor at Fudan University and The Chinese University of Hong Kong.
Dr. LEUNG obtained his BSc and Mphil in biochemistry, as well as EMBA from CUHK. He earned his D.Phil. in molecular biology from the University of Oxford in the UK in May 1989. He was also a postdoctoral fellow at Yale University in the US from July 1989 to June 1991.
Dr. Aldrin YIM is the founding CEO of Codex Genetics, with the mission to provide clinically actionable decisions through the generation of deep patient profiles. Aldrin is a neuroscientist, and received his Ph.D. at the Washington University School of Medicine. Through advanced genomics profiling approaches, Aldrin’s research work has revealed important molecular insights in neuropathies such as ALS. Aldrin has played an active role in accelerating the diagnosis of rare neurological disorders in HK. He was awarded the Spirit of Hong Kong Award in 2019 in recognition of his contribution to rare disease diagnosis and management.
Dr. Allen YU, Ph.D. is a Chevening Scholar 2017/18. He holds a PhD from The Chinese University of Hong Kong (CUHK), and an M.Sc. from Oxford. He is now serving as the founder and Chief Technology Officer of Codex Genetics. With support from ITC, HKSTP, and CUHK, Codex has transformed recent advances in genomics research into clinically actionable insights and provide personalised medicine service through AI and Big Data analytics.
15:00 – 16:00 Translational Research: From Concepts into Healthcare Innovation (Session II)
Moderators:
Professor Allen CHAN is Professor of Chemical Pathology at The Chinese University of Hong Kong. He is a co-inventor of the noninvasive prenatal test for Down syndrome and has pioneered the use of liquid biopsy for cancer screening. He is listed as one of the Top 20 Translational Researcher of the World by Nature Biotechnology in 2020 based on the number of granted patents. Professor CHAN is also an entrepreneur, having cofounded several biotechnology companies with Professors Dennis LO and Rossa CHIU.
Dr. Owen KO holds Bachelor of Medical Sciences (BMedSci), Bachelor of Medicine and Bachelor of Surgery (MBChB) from The Chinese University of Hong Kong (CUHK). He pursued PhD in neuroscience at University College London in the UK and won a runner-up award of the 2014 Eppendorf & Science Prize for Neurobiology based on his PhD works. Owen currently serves as a faculty member jointly appointed by the Department of Medicine and Therapeutics & School of Biomedical Sciences at CUHK, and a principal investigator at the Li Ka Shing Institute of Health Sciences. Leading a team with expertise in biology, chemistry and engineering, his research works focus on (i) gliovascular dysfunction in neurodegeneration and (ii) the development of new imaging tools for systems and translational neuroscience. His team’s recent research works have been recognized and supported by a 2020 Croucher Innovation Award, and a 2021 Excellent Young Scientists Fund from the National Natural Science Foundation of China.
Panelist:
Brad NELSON received the B.S. degree in Mechanical Engineering from the University of Illinois at Urbana-Champaign in 1984, the M.S. degree in Mechanical Engineering from the University of Minnesota in 1987, and the Ph.D. degree in Robotics from the School of Computer Science, Carnegie-Mellon University, Pittsburgh, PA, in 1995. He has been the Professor of Robotics and Intelligent Systems at ETH Zürich since 2002, where his research focuses on micro and nanorobotics with applications in biology and medicine. He has received a number of awards for his work in robotics, nanotechnology, and biomedicine.
16:00 – 16:30 Investment Opportunity
16:30 – 17:00 CU Medicine: A Platform for Realisation of Healthcare Innovation
Remarks:
The programme is subject to change without prior notice.
Registration
What are included in the Physical Summit Pass (participants who will attend the Summit in person)?
- Access to all sessions delivered in person in Hong Kong Science Park and to the videos available on the online platform for up to 3 months after the event
- Access to the Exhibition – Healthcare and innovation startups
- Guided Tour to InnoHK Centres and Experience Centre
(limited quota and preregistration is required)
What are included in the Online Summit Pass (participants who will attend the Summit online)?
- Access to livestreaming of Summit on online platform
- Access to the videos available on the online platform for up to 3 months after the event
Please note the following before registering for the Summit.
- Preregistration of the Summit is required.
- Registration is on a first-come, first-served basis. Participants may be assigned to watch livefeed of the Summit in other venues located at Hong Kong Science Park if the Charles K. Kao Auditorium is full.
- The programme and other event arrangement are subject to change without prior notice.
- Participants must wear their own surgical masks properly at all times (with nose, mouth and chin fully covered).
- Participants must comply with the HKSAR Government’s latest vaccine pass requirements.
- Participants need to have body temperature check before entering the Summit venue.
- Participants with high body temperature (>37.5°C) and/or acute respiratory tract infection symptoms, such as cough or shortness of breath are NOT permitted to attend the Summit.
- If you have been in close contact with any person who is a confirmed or preliminary positive case of COVID19 infection in the past 14 days, you are NOT permitted to attend the Summit.
- The seating of Summit venue will be limited according to the latest social distancing guidelines and requirements announced by the HKSAR Government.
Please visit HKSAR Government’s website for news and the latest arrangements in relation to COVID-19 in Hong Kong.
Exhibition – Start-up
Exhibiting CUHK Start-ups located at HKSTP from the below sectors:
Biotechnology
Health
Robotics
Artificial intelligence
Innovation
Big Data
What to expect?
Meet start-ups, industry experts, investors, healthcare professionals on site to exchange market intelligence
Have a glance on the latest innovative healthcare products and technology
Explore collaboration, investment, and research opportunities
Location:
Atrium Link, G/F, Building 10W, Phase 2, Hong Kong Science Park
Guided Tour to InnoHK Centres and Experience Centre @HKSTP
About InnoHK Centres
- In collaboration with world-renowned universities, such as Oxford, Cambridge, ETH Zürich, Imperial College London, Karolinska Institutet, the InnoHK Centres established under The Chinese University of Hong Kong are major contribution to Hong Kong’s development of innovation.
- Covering health, biomedicine, robotics and artificial intelligence, the InnoHK Centres with the state-of-the-art laboratories and facilities, apply research discoveries to realise ideas into commercialised healthcare products with a view to benefiting the community and building a better future of the healthcare system in Hong Kong.
About HKSTP Experience Centre
Featuring collective achievements, as well as evolving innovations and technologies, the state-of-the-art experiential space is an epitome of our vibrant I&T ecosystem with inspiring innovation stories being brought to life. Be inspired through an exclusive tech-empowered tour at the Experience Centre where visitors interact with real tech, discover pioneering I&T solutions and unwrap exciting opportunities with I&T. Embark on a new I&T journey to uncover hidden gems in Hong Kong’s largest R&D base.
With top-notch researchers from The Chinese University of Hong Kong (CUHK), University of Chicago, The University of Melbourne and University of Cambridge, the newly founded Microbiota I-Center (MagIC) focuses on advancing science in the gut microbiome and promoting entrepreneurship. It is committed to developing a novel class of microbiome diagnostics and live biotherapeutics for common diseases including obesity, cancer, autism, inflammatory disorders and COVID-19, that will not only transform lives of patients and their families, but also accelerate Hong Kong into a world-class microbiome biotechnology hub.
Non-local Collaborating Institutions: University of Cambridge, The University of Chicago and The University of Melbourne
Website: www.magic-inno.com
Positioned to enable translational research on and productisation of novel surgical robotic technologies, the Multi-Scale Medical Robotics Center (MRC) serves as a synergistic platform for transdisciplinary collaborations of clinicians, engineers, and researchers from local and overseas top-rank universities, through the R&D programmes of Endoluminal Multi-scale Robotic Platforms for Diagnostics and Therapeutics, Magnetic-guided Endoluminal Robotic Platform, and Imaged-Guided Robotic Interventions. The Hybrid Operating Room of the MRC Lab is a one-of-its-kind facility in Asia that is fully dedicated to R&D and preclinical evaluations of new surgical robots and medical devices via live animal and cadaveric studies.
Non-local Collaborating Institutions:ETH Zürich, Imperial College London, and Johns Hopkins University
Website: www.mrc-cuhk.com
The Center for Neuromusculoskeletal Restorative Medicine has been established to advance biomedical research and development related to neuromusculoskeletal medicine. Combining the expertise in stem cells, biomaterials, 3D bioprinting, tissue engineering, and personalised and translational medicine of The Chinese University of Hong Kong and Sweden’ s Karolinska Institutet , the Center is devoted to restoring structure and function to injured, diseased and degenerated (due to ageing or trauma) neuromusculoskeletal tissues and organs. This multi-disciplinary, international consortium aims to apply convergent principles and technologies of biomedical science and engineering to ultimately address mobility impairments and improve patients’ overall well-being.
Non-local Collaborating Institution: Karolinska Institutet
Website: https://www.cuhk.edu.hk/english/research/innohk-centres/neuromusculoskeletal.html
The Centre for Novostics (Novostics), with the meaning of novel diagnostics, aims to push forward the frontier of molecular diagnostics. Novostics will focus on the development of cutting edge diagnostics based on cell-free nucleic acids in blood and other bodily fluids, particularly around prenatal diagnosis and cancer diagnostics.
With its experience in developing prenatal testing of fetal chromosome disorders, the Centre plans to extend the work to single gene disease and other pregnancy-associated conditions. A combination of genomic, epigenomic, trancriptomic and fragmentomic technologies will be employed to tackle bottlenecks in cancer diagnostics and investigate the tissue origin of malignancy by circulating nucleic acid analysis, particularly for cancer types prevalent in Hong Kong, mainland China and Asia. These research areas will accelerate the application of liquid biopsy and promote Hong Kong as a leading molecular diagnostic centre in the world.
Non-local Collaborating Institutions: University of Oxford, UCL Great Ormond Street Institute of Child Health, Great Ormond Street Hospital for Children NHS Foundation Trust, and Imperial College London
Website: www.novostics.hk
- WHERE INNOVATIONS ARE FOUND
- Learn how pioneering tech solutions tackle the world’s most pressing challenges and transform our lives through Tech for Good innovations.
- WHERE FUTURE IS CREATED
- Witness tech from HKSTP challenges the boundaries of modern innovation, revolutionises traditional industries and reaches beyond borders to make global impact.
- WHERE TALENT FLOURISHES
- Hong Kong Science Park is where innovative minds gather, spark ideas and co-create. Discover park talents’ success stories and be inspired to unlock your opportunities with I&T.
Website: https://www.hkstp.org/our-community/park-life/experience-centre/
Schedule of visit:
If you are interested in joining the guided tour, please register HERE.
